Ken Garber. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Antibodies, Monoclonal/therapeutic useAntigens, CD/drug effectsCTLA-4 AntigenClinical Trials, Phase I as TopicClinical Trials, Phase III as TopicDrug Industry/trendsHumansIndoles/therapeutic useIpilimumabMelanoma/immunologyMelanoma/therapyProtein Kinase InhibitorsProto-Oncogene Proteins B-raf/antagonists & inhibitorsSkin Neoplasms/immunologySkin Neoplasms/therapySulfonamides/therapeutic useTreatment OutcomeVemurafenib
Substances： See more » Antibodies, MonoclonalAntigens, CDCTLA-4 AntigenCTLA4 protein, humanIndolesIpilimumabProtein Kinase InhibitorsSulfonamidesVemurafenibBRAF protein, humanProto-Oncogene Proteins B-raf
Year: 2010 PMID： 20697383 DOI： 10.1038/nbt0810-763
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908